Pharmacological characteristics of Ro 115-1240, a selective α 1A/1L-adrenoceptor partial agonist: A potential therapy for stress urinary incontinence

BJU International

Volumn 93, Issue 1, 2004, Pages 162-170

  Blue, D R ^a   Daniels, D V ^a   Gever, J R ^a   Jett, M F ^a   O'Yang, C ^a   Tang, H M ^a   Williams, T J ^a   Ford, A P D W ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

adrenoceptor; Blood pressure; Stress urinary incontinence; Urethral smooth muscle

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; AMIDEFRINE; DABUZALGRON; IMIDAZOLINE DERIVATIVE; RECEPTOR SUBTYPE;

ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HEART RATE; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; STRESS INCONTINENCE; SWINE; URETHRA PRESSURE;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FEMALE; HEART RATE; IMIDAZOLES; MALE; MODELS, BIOLOGICAL; PRAZOSIN; RABBITS; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES; SWINE; SWINE, MINIATURE; URINARY INCONTINENCE, STRESS;

EID: 1642538361     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04577.x     Document Type: Article

References (37)

1. Cheater FM, Castleden CM. Epidemiology and classification of urinary incontinence. Best Prac Res Clin Obstetrics Gynaecol 2000; 14: 183-205
2. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
3. Dawson C, Whitfield H. Urinary incontinence and urinary infection. In ABC of Urology. London: BMJ Books, 1997: 19-21
4. Stanton SL. Stress urinary incontinence. Ciba Found Symp 1990; 151: 182-9
5. Hieble JP, Bylund DB, Clarke DE et al. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 1995; 47: 267-70
6. Chess-Williams R, Aston N, Couldwell C. Alpha 1A-adrenoceptor subtype mediates contraction of the rat urethra. J Auton Pharmacol 1994; 14: 375-81
7. Auguet M, Delaflotte S, Chabrier PE. Different alpha1-adrenoceptor subtypes mediate contraction in rabbit aorta and urethra. Eur J Pharmacol 1995; 287: 153-61
8. Yoshida M, Latifpour J, Nishimoto T, Weiss RM. Pharmacological characterization of alpha adrenergic receptors in the young and old female rabbit urethra. J Pharmacol Exp Ther 1991; 257: 1100-8
9. Alberts P, Bergstrom PAC, Fredrickson MG. Characterisation of the functional α-adrenoceptor subtype in the isolated female pig urethra. Eur J Pharmacol 1999; 371: 31-8
10. 1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs. Eur J Pharmacol 1996; 318: 117-22
11. Modiri AR, Fredrickson MG, Gillberg PG, Alberts P. Selectivity of oxymetazoline for urethral pressure vs blood pressure in the anaesthetized female rabbit. Scand J Urol Nephrol 2000; 34: 151-6
12. Flavahan NA, Vanhoutte PM. Alpha1-adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol Sci 1986; 7: 347-9
13. Muramatsu I, Ohmura T, Kigoshi S, Hashimoto S, Oshita M. Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle. Br J Pharmacol 1990; 99: 197-201
14. Ford AP, Daniels DV, Chang DJ et al. Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification. Br J Pharmacol 1997; 121: 1127-35
15. Kava MS, Blue DR Jr, Vimont R, Clarke DE, Ford APDW. α1L- Adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. Br J Pharmacol 1998; 123: 1359-66
16. Ford AP, Arredondo NF, Blue DR Jr. et al. RS-17053 (N-[2-(2- cyclopropylmethoxyphenoxy) ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3- ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol 1996; 492: 209-15
17. Andersson KE, Persson CGA, Alm P, Kullander S, Ulmsten U. Effects of acetylcholine, noradrenaline, and prostaglandins on the isolated, perfused human fetal urethra. Acta Physiol Scand 1978; 104: 394-401
18. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255-63
19. 1A-adrenoceptor selective antagonists. Br J Pharmacol 1999; 127: 252-8
20. 1A-adrenoceptor antagonist, does not improve lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2002; 167 (Suppl.): 265
21. Marshall HJ, Beevers DG. Alpha-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility. Br J Clin Pharmacol 1996; 42: 507-9
22. Diokno AC, Taub M. Ephedrine in treatment of urinary incontinence. Urology 1975; 5: 624-5
23. Ek A, Andersson KE, Gullberg B, Ulmsten U. The effects of long-term treatment with norephedrine on stress incontinence and urethral closure pressure profile. Scand J Urol Nephrol 1978; 12: 105-10
24. Jonas D. Treatment of female stress incontinence with midodrine: preliminary report. J Urol 1977; 118: 980-2
25. Weil EHJ, Eerdmans PHA, Dijkman GA et al. Randomized double-blind placebo-controlled multicenter evaluation of efficacy and dose finding of midodrine hydrochloride in women with mild to moderate stress urinary incontinence: a phase II study. Int Urogynecol J Pelvic Floor Dysfunc 1998; 9: 145-50
26. Radley SC, Chapple CR, Bryan NP, Clarke DE, Craig DA. Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study. Neurourol Urodyn 2001; 20: 43-52
27. Andersson KE, Sjogren C. Aspects on the physiology and pharmacology of the bladder and urethra. Prog Neurobiol 1982; 19: 71-89
28. Andersson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253-308
29. Cournoyer RL, Keitz PF, O'Yang C, Yasuda DM. 2-Imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and aminophenyl alkylsulfonnamides and ureas and their use. US Patent No. 5,952,362 Sept 14, 1999:1-73
30. 50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108
31. Brown E, Kendall D, Nahorski SR. Inositol phospholipid hydrolysis in rat cerebral cortical slices. I. Receptor characterisation. J Neurochem 1984; 42: 1379
32. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction, 3rd edn. Philadelphia: Lippincott-Raven Publishers, 1997
33. Blue DR Jr, Bonhaus DW, Ford APDW et al. Functional evidence equating the pharmacologically-defined 1A-and cloned 1A-adrenoceptor: studies in the isolated perfused kidney of rat. Br J Pharmacol 1995; 115: 283-94
34. Brune ME, O'Neill AB, Gauvin DM et al. Comparison of α1- adrenoceptor agonists in canine urethral pressure profilometry and abdominal leak point pressure models. J Urol 2001; 166: 1555-9
35. Eltze M, Boer R. The adrenoceptor agonist SDZ NVI 085 discriminates between alpha 1A-and alpha 1B-adrenoceptor subtypes in vas deferens, kidney and aorta of rat. Eur J Pharmacol 1992; 224: 125-36
36. 1A receptor subtype. J Pharmacol Exp Ther 1995; 274: 97-103
37. Garofalo F, Lalanne GM, Nanni G. Midodrine for female incontinence: a preliminary report. Clin Ther 1986; 9: 44-6